PIPELINE
Candidate R&D
Preclinical
Clinical Phase 1/2
Technology Tranfer
Clinical Phase 3
Product Sales
Candidate R&D
Discovery and Acquisition
Preclinical
Clinical Phase 1/2
Clinical Phase 3
Product Sales
Technology Tranfer / M&A
Candidate R&D
Candidate R&D
Preclinical
Preclinical
Clinical Phase 1/2
Clinical Phase 1/2
Clinical Phase 3
Product Sales
Technology Tranfer
Clinical Phase 3
Product Sales
Technology Tranfer
R&D stage
Promotion year
Promotion contents
Promotion schedule
2022
2023
2024
2025
One 2 3 4 5 6 7 8 9 10 11 12
6 types of Dimeric including CarBio-101, 102 lymphoma, CarBio-201 pancreatic cancer
CAR vector production (consignment)
6 types including CarBio-101, 102 lymphoma, CarBio-201 pancreatic cancer
Verification and tri-category
3 types including CarBio-101, 102 lymphoma, CarBio-201 pancreatic cancer
Screening and building in vitro assays
CarBio-101, 102 lymphoma, CarBio-201 3 types of pancreatic cancer
in vitro efficacy test
CarBio-101 and -102 lymphoma, CarBio-201 3 types of pancreatic cancer
Biodistribution/toxicity safety test
CarBio-202 Breast/ovarian cancer CarBio-201 Pancreatic cancer
CarBio-201 CarBio-202 non-clinical trial
CarBio-101 and -102 Clinical Trial Preparation
CarBio-101 and -102 2 types of IND application
CarBio-301 Candidates for head and neck cancer
CarBio-301 head and neck cancer non-clinical trial
CarBio-302 Lung Cancer and -401 Dementia Candidates
CarBio-302 lung cancer non-clinical trial
CarBio-101 and -102 lymphoma, CarBio-201 3 types of pancreatic cancer, and
In vitro/in vivo preparation
CarBio-103 Lupus treatment in vitro efficacy test
Non-clinical trial of CarBio-103 Lupus treatment
CarBio-101 and -102 lymphoma, three types of CarBio-201 pancreatic cancer in vivo
Animal model efficacy test
2026
CarBio-101 and -102 type 2 clinical trial phase 2
CarBio-201 and -202 2 types IND
CarBio-301 and -302 IND
CarBio-401 non-clinical